N
Nan Lin
Researcher at Harvard University
Publications - 1220
Citations - 65601
Nan Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 105, co-authored 687 publications receiving 54545 citations. Previous affiliations of Nan Lin include University of Michigan & Fujian Medical University.
Papers
More filters
Journal ArticleDOI
A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105).
Carlos L. Arteaga,Ingrid A. Mayer,Anne O'Neill,Ramona F. Swaby,R. Katherine Alpaugh,Ximing J. Yang,Lynne I. Wagner,Neal J. Meropol,Thomas James Saphner,Mohammad Jahanzeb,Edith A. Perez,Nan Lin,George W. Sledge +12 more
TL;DR: A randomized double-blinded phase III trial to evaluate efficacy (PFS after treatment initiation) of the addition of bevacizumab in first-line treatment of HER2+ MBC and results are summarized on the tables below.
Journal Article
The Neurologic Assessment in Neuro-Oncology (NANO) Scale: A Tool to Assess Neurologic Function for Integration in the Radiologic Assessment in Neuro-Oncology (RANO) Criteria (S22.005)
Lakshmi Nayak,Lisa M. DeAngelis,Patrick Y. Wen,Alba A. Brandes,Riccardo Soffietti,Nan Lin,David M. Peereboom,Marc C. Chamberlain,David W. Macdonald,Evanthia Galanis,James Perry,Kurt A. Jaeckle,Minesh P. Mehta,Roger Stupp,Martin J. van den Bent,David A. Reardon +15 more
TL;DR: The NANO criteria provide a more detailed and objective measure of Neurologic function than currently exists for brain tumor patients and enable a consistent evaluation of neurologic function that can be assessed across clinical trials and therapeutic interventions.
Journal ArticleDOI
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Tanya Keenan,Tanya Keenan,Tanya Keenan,Jennifer L. Guerriero,Jennifer L. Guerriero,Romualdo Barroso-Sousa,Romualdo Barroso-Sousa,Tianyu Li,Tess O’Meara,Tess O’Meara,Anita Giobbie-Hurder,Nabihah Tayob,Jiani Hu,Mariano Severgnini,Judith Agudo,Ines Vaz-Luis,Leilani Anderson,Leilani Anderson,Victoria Attaya,Victoria Attaya,Jihye Park,Jihye Park,Jake Conway,Jake Conway,Meng Xiao He,Meng Xiao He,Brendan Reardon,Brendan Reardon,Erin Shannon,Gerburg M. Wulf,Laura Spring,Rinath Jeselsohn,Rinath Jeselsohn,Ian E. Krop,Ian E. Krop,Nan Lin,Nan Lin,Ann H. Partridge,Ann H. Partridge,Eric P. Winer,Eric P. Winer,Elizabeth A. Mittendorf,David Liu,David Liu,Eliezer M. Van Allen,Eliezer M. Van Allen,Sara M. Tolaney,Sara M. Tolaney +47 more
TL;DR: The final overall survival (OS) results from a randomized phase 2 trial of eribulin and pembrolizumab for patients with metastatic HR+breast cancer, computationally dissect genomic and/or transcriptomic data from pre-treatment tumors, and identify cytokine changes differentiating response and ICI-related toxicity.
Journal ArticleDOI
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.
Ayal A. Aizer,Nayan Lamba,Manmeet Ahluwalia,Kenneth Aldape,Adrienne Boire,Priscilla K. Brastianos,D. D. Brown,D. Ross Camidge,Veronica Chiang,Michael Davies,Leland S. Hu,Raymond Y. Huang,Timothy J. Kaufmann,Priya Kumthekar,Keng Lam,Eudocia Q. Lee,Nan Lin,Minesh P. Mehta,Michael W. Parsons,David A. Reardon,Jason P. Sheehan,Riccardo Soffietti,Hussein Abdul-Hassan Tawbi,Michael Weller,Patrick Y. Wen +24 more
TL;DR: The hope is that these consensus guidelines will accelerate progress in the understanding and management of patients with brain metastases, and highlight key areas in need of further exploration that will lead to dedicated trials and other research investigations designed to advance the field.